Study of WGb-0301 for B-cell blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment, WGb-0301, for people with B-cell lymphoma or leukemia that has come back or not responded to other therapies. It aims to see if this therapy can help when standard options are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have B-cell lymphoma or leukemia that is CD19-positive and has not responded to standard treatments.
- You are expected to live at least 12 more weeks.
- You are in generally good health (able to do daily activities).
- You have not received CAR T-cell therapy before.
- You do not have an active infection with HIV, hepatitis B, or hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy called WGb-0302 for people with multiple myeloma that has come back or is not responding to other treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new medicine called WGb-0301 for people with relapsed or hard-to-treat immune diseases like lupus, autoimmune hepatitis, inflammatory muscle disease, or scleroderma. It may help when standard treatments have stopped working.
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This trial tests a new drug called ZZSW-01 for people with certain B-cell blood cancers (like lymphoma or leukemia) that have come back or haven't gotten better after other treatments. It aims to see if the drug is safe and works against these cancers.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.